BlackDiamond Wealth Management LLC Has $207,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

BlackDiamond Wealth Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 10.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 795 shares of the medical research company’s stock after selling 94 shares during the quarter. BlackDiamond Wealth Management LLC’s holdings in Amgen were worth $207,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Argent Advisors Inc. grew its holdings in Amgen by 1.1% during the 4th quarter. Argent Advisors Inc. now owns 4,172 shares of the medical research company’s stock worth $1,087,000 after acquiring an additional 47 shares during the period. Cozad Asset Management Inc. grew its holdings in shares of Amgen by 5.9% in the 4th quarter. Cozad Asset Management Inc. now owns 1,795 shares of the medical research company’s stock valued at $468,000 after buying an additional 100 shares during the period. Horizon Kinetics Asset Management LLC grew its holdings in shares of Amgen by 4.1% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 3,597 shares of the medical research company’s stock valued at $938,000 after buying an additional 141 shares during the period. 1ST Source Bank grew its holdings in shares of Amgen by 4.0% in the 4th quarter. 1ST Source Bank now owns 2,988 shares of the medical research company’s stock valued at $779,000 after buying an additional 116 shares during the period. Finally, Cibc World Markets Corp grew its holdings in shares of Amgen by 3.8% in the 4th quarter. Cibc World Markets Corp now owns 238,112 shares of the medical research company’s stock valued at $62,062,000 after buying an additional 8,811 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AMGN. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $314.04.

Amgen Stock Up 1.1 %

Shares of AMGN opened at $317.17 on Tuesday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market cap of $170.39 billion, a P/E ratio of 42.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The firm’s 50-day simple moving average is $292.99 and its 200 day simple moving average is $299.02. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.